Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Duality Biologics Adds Third ADC Candidate to BioNTech Partnership

publication date: Aug 7, 2023

Duality Biologics (Suzhou) added a third antibody-drug conjugate candidate to its partnership with BioNTech, the German mRNA COVID vaccine company. BioNTech will now have global rights (ex-China) to DB-1305, a third generation Trop2 ADC molecule that has shown clinical efficacy in NSCLC and other solid tumors. In April, BioNTech in-licensed global (ex-China) rights for two ADC candidates from Duality in a $1.7 billion deal ($170 million upfront). In the latest agreement, Duality will receive an upfront payment and be eligible for milestones and royalties, though specific details were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital